Myriad Genetics

  • 3 Notable Upgrades on Wednesday

    By Brian Nichols - June 27, 2013 | Tickers: MYGN, RAX, WDAY

    On a day-to-day basis, there are countless analyst calls – some of which are good and others that are bad – and in this piece, I am looking at three in particular to determine if any are good and present value for investors.

    A “responsible” call of caution

    Since June 12, shares of Myriad Genetics (NASDAQ: MYGN) have traded lower by more than 20%. This loss has come after the Supreme Court more »

  • Big Pharma's Intellectual Property Blues

    By Leo Sun - June 18, 2013 | Tickers: MYGN, NVS, PFE

    It’s not easy being a biotech company. Every year, the biotech industry pours billions of dollars in research and development costs towards creating cutting edge drugs that treat major diseases. If these drugs are approved, then they are patented, sometimes becoming best-selling medications that generate even more revenue to aid further research.

    However, when these big pharmaceutical companies create tests and drugs that can treat major, life-threatening diseases such more »

  • Judgment Day for Myriad Genetics

    By Kanak Kanti - June 5, 2013 | Tickers: ILMN, MYGN, QGEN

    Can we patent human genomes? This sounds so academic, except that the future of at least one biotech company hinges on an answer to this question.

    On June 30, the Supreme Court is going to make a decision on a case filed by the Association for Molecular Biology on human genome patentability against Myriad Genetics (NASDAQ: MYGN), a $2.57 billion molecular diagnostic company.

    What will happen to its stock more »

  • Splicing & Dicing Myriad Genetics Amidst the Angelina Jolie Disclosure

    By BA McKenna - May 20, 2013 | Tickers: ILMN, MYGN

    Myriad Genetics (NASDAQ: MYGN) and the topic of genetic testing to determine one's risk of disease was in the spotlight last week thanks to film star Angelina Jolie. Myriad's no stranger to the biotech spotlight given its Supreme Court case pertaining to whether human genes can be patented, but Jolie put genetic testing front and center in the public view. 

    One has to give credit to Jolie for more »

  • Do These Top Stock Picks Have More Room to Grow?

    By Brian Nichols - May 13, 2013 | Tickers: ACT, MYGN, RH, THRX

    I began using Motley Fool’s “CAPS” late last year as a way for readers to track my new positions and to show the outcome of my investments that were chosen based on the information found in my book, Taking Charge With Value Investing (McGraw-Hill, 2013). The CAPS scores allow you to track your selections up against the market, with the higher number being the better, with perfection being 100 more »

  • Is This Ticking Time Bomb A Cornerstone of Your Portfolio?

    By Brendan O'Boyle - April 18, 2013 | Tickers: LH, LPNT, MYGN

    The Supreme Court is scheduled to hear a greatly anticipated case that will provide clarity on the patentability of human genes. Over the past thirty years, biotechnology innovators have secured patents on genes for purposes that range from medical to agricultural products. This Monday, a challenge to Myriad Genetics (NASDAQ: MYGN) was heard contesting whether or not their patent is valid. The Association for Molecular Pathology is challenging the patentability more »

  • Is This Ticking Time Bomb A Cornerstone of Your Portfolio?

    By Brendan O'Boyle - April 14, 2013 | Tickers: MYGN

    The Supreme Court is scheduled to hear a greatly anticipated case that will provide clarity on the patentability of human genes. Over the past thirty years, biotechnology innovators have secured patents on genes for purposes that are diverse ranging from medical to agricultural products. On Monday, a challenge to Myriad Genetics (NYSE: MYGN) will be heard contesting whether their patent is valid. The Association for Molecular Pathology is challenging the more »

  • Invest in the Spending Trends of the Wealthy

    By Lee Samaha - March 10, 2013 | Tickers: AGN, SAM, LULU, MYGN, WFM

    I have a quick trivia question. What share of total US net worth does the bottom 60% of US citizens (ranked by net worth) hold? The answer is just 4.2%, while the top 5% of US citizens (again ranked by net worth) owns nearly 62%.

    Now consider an average superstore in an average mall (such a thing doesn’t actually exist, but assume it does), and accept that spending more »

  • 2 to Buy & 1 to Sell After Earnings on Monday

    By Brian Nichols - March 5, 2013 | Tickers: MYGN, SNTS, SSYS

    Monday was a somewhat slow day in terms of companies reporting earnings; however like all days during earnings season, opportunity still presented itself. Earnings season is a period where retail investors can either capitalize on great opportunity or can be suckered by what looks like value. In this piece, I am looking at both, one stock that should be avoided, and two stocks to buy.

    Speculation and Modest Growth is more »

  • What the Bioeconomy Means for Investors

    By Maxxwell A.R. Chatsko - November 27, 2012 | Tickers: AMRS, CERE, LIFE, MON, MYGN, SZYM | Editor's Choice

    On April 1, the White House released the National Bioeconomy Blueprint (opens PDF) that outlined the importance of transitioning health/life science, chemical production, agriculture, and other industries into the 21st century. Yes, it was April Fool’s Day. No, the White House wasn’t joking.

    Despite being lost in the midst of an election year the message was clear: an American bioeconomy can transform the world. The report more »

  • Repeat After Me: My Genes are Patentable and That's Alright

    By Maxxwell A.R. Chatsko - September 12, 2012 | Tickers: BMY, INCY, MYGN, PFE

    The recent Association for Molecular Pathology v. Myriad Genetics patent dispute involving two genes for breast and ovarian cancer, BRCA 1 and BRCA 2, has been widely followed by the media over the last several years. According to some the case highlights a potentially devastating future where humans have no control over their very own genetic code. Even worse, they say, patenting sequences of human DNA limits academic research and more »

  • A Fast Growing Diagnostics Company but Why is it So Cheap?

    By Lee Samaha - August 22, 2012 | Tickers: ABT, CPHD, ILMN, LIFE, MYGN

    Myriad Genetics (NASDAQ: MYGN) offers an interesting investment proposition. On the one hand it is a fast growing and highly cash generative company with strong future prospects. On the other, it is a company which is fraught with legal challenges to its patents and whose growth prospects are largely dependent on the reimbursement agenda of the managed care industry. Sometimes the hardest part in investing is quantifying risk and it more »

  • Great Values Among Battered Medical Technology Stocks

    By Streetwise Reports - April 19, 2012 | Tickers: BIO, GE, MYGN, SQNM, VAR

    Subscribe to The Life Sciences Report for more interviews with life sciences and biotech analysts.

    --------------

    George S. Mack, The Life Sciences Report

    A new device must offer a tangible bottom-line advantage.

    No industry in the healthcare sector has been shrouded with more pessimism than medical technology. It would be easy to check off all the boxes on your list of gloomy headwinds, dust off your hands and find another story more »

  • Keryx: A Great Pick For Aggressive Investors

    By Bobby Fisher - March 26, 2012 | Tickers: CRIS, KERX, MDVN, MYGN

    There’s something to be said for investing in companies that have admirable objectives. Keryx Pharmaceuticals (NASDAQ: KERX) is trying to help cure bowel cancer. It’s a worthy goal given that the recovery prospects for patients at this moment are bleak. But does that make Keryx stock a great investment?

    The company’s stock has soared in the last few weeks with news of impending data from their phase more »

  • Healthcare Stocks and the January Effect

    By Brandy Betz - December 30, 2011 | Tickers: ALXA, ASTX, CBRX, MYGN, QCOR

    The January Effect refers to a raise in small-cap stock prices that can occur in the first month of the year thanks to the tax inspired investor sell-offs in December. This occurrence isn’t as prevalent as it once was due to the market’s ability to adjust. But a recovering economy and notable healthcare industry events could move investors towards small-cap pharma and biotech stocks in the early months more »